Tvardi Therapeutics to Participate at the 2024 BTIG Virtual Biotechnology Conference
2024年7月31日 - 10:30PM
ビジネスワイヤ(英語)
Tvardi Therapeutics, Inc. (“Tvardi”), a privately held,
clinical-stage biopharmaceutical company focused on the development
of STAT3 inhibitors, announced that Imran Alibhai, PhD, Chief
Executive Officer of Tvardi Therapeutics will participate in a
fireside chat at the 2024 BTIG Virtual Biotechnology Conference on
Tuesday, August 6, 2024, at 10:00 AM ET.
In addition to the fireside chat, the management team will hold
one-on-one investor meetings Monday and Tuesday, August 5-6, 2024.
If you are interested in meeting with the Tvardi Therapeutics
management team during the conference, please reach out to
BTIG.
About Tvardi Therapeutics
Tvardi is a privately held, clinical-stage biopharmaceutical
company developing small molecule inhibitors of STAT3, a key
regulatory protein positioned at the intersection of many signaling
pathways integral to the survival and immune evasion of cancer
cells. STAT3 also plays a central role in the pathogenesis of many
inflammatory and fibrotic diseases. The company is conducting Phase
2 clinical trials in STAT3-driven diseases: hepatocellular
carcinoma (NCT05440708) and idiopathic pulmonary fibrosis
(NCT05671835). To learn more, please visit tvardi.com or follow us
on LinkedIn and X (Twitter).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240731971312/en/
Tvardi Investor Relations Sara Manning ir@tvardi.com